Medications like Ozempic or Wegovy and Zepbound or Mounjaro are changing the game in the fight against obesity, enabling significant and sustained weight loss
The study, which was published Wednesday in the journal BMJ Medicine, underscores the need to maintain treatment with GLP-1 medications to continue to see their benefits
Semaglutide has previously been shown in the SELECT trial to significantly reduce major adverse cardiovascular events in overweight/obese patients with known heart disease but without diabetes, Chen explained
Mounjaro has UK marketing authorisation for chronic weight management, but NHS availability is determined by NICE guidance
L-CARNITINA: ALM DO METABOLISMO DE LIPDIOS
This is due to its antioxidant properties, which can interfere with the oxidative damage that chemotherapy drugs aim to induce in cancer cells